The extracellular immunogenic subunit (25 A.A.)of MUC1 combined with the nonspecific adjuvant monophosphoryl lipid A and three different lipids was combined together to prepare a therapeutic lung cancer vaccine called liposomal BLP25 (L-BLP25, Stimuvax) [64, 65]. Here, MUC1 is linked to lung carcinoma.